Accession Number: | 0001104659-19-052307 |
Date: | 2019-09-30 |
Issuer: | ABBVIE INC. (ABBV) |
Original Submission Date: |
ALPERN ROBERT J
1 N. WAUKEGAN ROAD
NORTH CHICAGO, IL 60064
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
STOCK EQUIVALENT UNITS | 0.0 | 2019-09-30 | deemed execution date | A | 90 (a) | common stock 90 | $0.00 | 6,773 | direct |
ID | footnote |
---|---|
f1 | director fees credited to stock equivalent unit accounts under grantor trusts established by the director at abbott laboratories and abbvie. the stock equivalent units in the abbott account will be paid, in cash, generally at age 65 or upon retirement from abbott's board, and the stock equivalent units in the abbvie account will be paid, in cash, generally at age 65 or upon retirement from abbvie's board. the stock equivalent units in each account earn the same return as if the fees were invested in abbvie stock. |
f2 | balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. |